# Premier Air Charter Holdings Inc.: Form 10-K for the period ended Mar 31, 2017

- Company: [Premier Air Charter Holdings Inc.](/companies/prem.md) (CIK 1570937)
- Form: 10-K
- Filed: 2018-08-17
- Accepted by EDGAR: Aug 17, 2018, 19:14 ET
- Period: 2017-03-31
- Accession: 0001554795-18-000235
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1570937/000155479518000235/atao0808form10k17.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1570937/000155479518000235/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Interest expense | 12 months, 2016-04-01 to 2017-03-31 | $138.0k | us-gaap:InterestExpense |
| Net income | 12 months, 2016-04-01 to 2017-03-31 | −$736.8k | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2016-04-01 to 2017-03-31 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months, 2016-04-01 to 2017-03-31 | −$59.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2017-03-31 | $7.5k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-03-31 | $7.5k | us-gaap:AssetsCurrent |
| Total assets | at 2017-03-31 | $7.5k | us-gaap:Assets |
| Current liabilities | at 2017-03-31 | $648.8k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-03-31 | $648.8k | us-gaap:Liabilities |
| Shareholders' equity | at 2017-03-31 | −$641.2k | us-gaap:StockholdersEquity |

## Business

As filed, 4,005 characters.

### Our Business

The Company is currently engaged in identifying and assessing new business opportunities.

On November 11, 2014, the Company entered into a strategic alliance with Cure Pharmaceutical Corporation (“CURE”), a California company engaged in the development of oral thin film (“OTF”) for the delivery of nutraceutical, over-the-counter and prescription products. Initially this alliance was comprised of an Exclusive License and Distribution Agreement for CURE’s Sildenafil (commonly known as Viagra) Products throughout Asia, Brazil, the Middle East and Canada acquired at a cost of $200,000 while a joint venture agreement for the procurement of converting and packaging equipment specific for oral thin film products was proposed through a Letter of Intent. In addition, Altair and Cure agreed to enter into further joint ventures or other business relationships for the purpose of completing the development and marketing of additional products, and for license and distribution agreements for additional Cure products such as aspirin, sleep-aid, topical muscle and joint pain relief, and electrolytes delivered through OTF or other methods. Altair advanced $360,000 to CURE in this regard.

On September 23, 2016, the Company and CURE agreed to terminate the Exclusive License and Distribution Agreement for CURE’s Sildenafil Products due to unanticipated costs of obtaining regulatory approvals for the introduction of these pharmaceutical products into the licensed markets. The Company and CURE agreed to replace it with an Exclusive License and Distribution Agreement for a family of sports related nutraceutical products including a topical active for joint and muscle pain and OTF products for delivery of electrolyte, energy, sleep and recovery actives. The Company was to become the exclusive worldwide distributor for these products. The fee for this new sport products agreement was $560,000, comprised of the $200,000 fee paid for the Sildenafil agreement and the $360,000 advanced as a deposit for future license and distribution agreements. The agreement called for minimum orders of the products by Altair of $1,500,000 in the twenty-four months from the date of signing. As of June 29, 2018, the Company has been unable to generate any sales of the products due to a lack of working capital and the human resources required to introduce the products to market. The Company anticipates that it will not meet the minimum order requirements for the initial 24 month period and accordingly has written off its $560,000 investment in the agreement in these financial statements for the year ended March 31, 2017.

The Company had previously planned to commence operations in the architectural field and to be responsible for the concept architectural vision of future private and public buildings as well as municipal organized public areas. This plan was abandoned in the 2015 fiscal year in favor of the business operations described above.

### Property Acquisitions

None

### Intellectual Property

The Company does not own any intellectual property and has yet to incur any expenses for research and development other than as disclosed herein.

### Employees

As of the date of this Report, the Company has no full-time nor part-time employees. Our sole officer and director does not have a current agreement with the Company to serve in these capacities. We intend to increase the number of our employees and consultants to meet our needs as the Company grows.

### WHERE YOU CAN GET ADDITIONAL INFORMATION

We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy our reports or other filings made with the SEC at the SEC’s Public Reference Room, located at 100 F Street, N.W., Washington, DC 20549. You can obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. You can also access these reports and other filings electronically on the SEC’s web site, www.sec.gov.

## Management's discussion and analysis

As filed, 7,870 characters.

The following discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward looking statements. Our audited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

RESULTS OF OPERATIONS

We have incurred recurring losses to date. Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation.

We expect we will require additional capital to meet our long term operating requirements. We expect to raise additional funds through, among other things, the sale of equity or debt securities although no assurance can be given as to the availability of funds or the terms thereof.

FISCAL YEAR ENDED MARCH 31, 2017 COMPARED TO FISCAL YEAR ENDED MARCH 31, 2016

Our net loss for the fiscal year ended March 31, 2017 was $736,744 compared to a net loss of $153,827 for the fiscal year ended March 31, 2016 (restated). During fiscal years ended March 31, 2017 and March 31, 2016, the Company did not generate any revenue.

During the fiscal year ended March 31, 2017, we incurred general and administrative expenses of $80,253 compared to $43,099 in general and administrative expenses incurred during the fiscal year ended March 31, 2016 (restated).

Expenses incurred during fiscal year ended March 31, 2017 compared to the fiscal year ended March 31, 2016 increased primarily due to the increased scale and scope of business operations. General and administrative expenses generally include corporate overhead and financial and administrative contracted services.

The weighted average number of shares outstanding was 30,902,589 for the fiscal year ended March 31, 2017 and 29,796,760 for the fiscal year ended March 31, 2016.

LIQUIDITY AND CAPITAL RESOURCES

FISCAL YEAR ENDED MARCH 31, 2017

As of March 31, 2017, our current assets were $7,523 and our total liabilities were $648,763. As of March 31, 2017, current assets were comprised of $7,523 in cash. As of March 31, 2017, total liabilities were comprised of $21,590 in accounts payable, loans payable to third parties of $14,165, interest payable of $12,575, promissory notes for $292,299, and a derivative liability of $308,134. As of March 31, 2017, our total assets were comprised of $7,523 in cash. Stockholders’ deficit was $641,240 as of March 31, 2017.

As of March 31, 2016, our current assets were $5,422 and our total liabilities were $519,988 (restated). As of March 31, 2016, current assets were comprised of $5,422 in cash. As of March 31, 2016, total liabilities were comprised of $14,089 (restated) in accounts payable, loans payable to third parties of $40,525, interest payable of $21,000, a promissory note for $100,000 due to a third party, a derivative liability of $100,000 and $244,374 in advances from a related party. As of March 31, 2016, our total assets were $565,422 comprised of $5,422 of cash, a sales and distribution license of $200,000 and advances to Cure Pharmaceuticals of $360,000. Stockholders’ equity was $45,434 as of March 31, 2016.

#### Cash Flows from Operating Activities

We have not generated positive cash flows from operating activities. For the fiscal year ended March 31, 2017 net cash flows used in operating activities were $58,983 consisting of a net loss of $736,774, the write off of sales and distribution licenses in the amount of $560,000, increases of $21,270 in accounts payable, $12,674 in interest payable, and $125,364 in debt discount, and a decrease of $41,517 in the fair value of derivative liabilities.

We did not generate positive cash flows from operating activities in the year ended March 31, 2016. For the fiscal year ended March 31, 2016 (restated) net cash flows used in operating activities were $71,257 consisting of a net loss of $153,827, a decrease of $651 in accounts payable, and increases of $11,000 in interest payable, and $72,221 in debt discount.

#### Cash Flows from Financing Activities

We have financed our operations primarily from either advances from shareholders or the issuance of equity and debt instruments. For the year ended March 31, 2017 cash was provided from (used for) financing activities including net repayment of loans from third parties of $(12,510), proceeds of $43,594 from the issuance of promissory notes and proceeds from common stock subscriptions of $30,000.

For the year ended March 31, 2016 (restated) cash was provided from financing activities including loans from third parties of $40,525 and proceeds of $265,006 from the issuance of common stock. The Company repaid $109,052 in advances from a shareholder.

PLAN OF OPERATION AND FUNDING

We expect that working capital requirements will continue to be funded through a combination of our existing funds, advances from shareholders and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business.

Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next six months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business); (ii) acquisition of assets; and (iii) sales and marketing expenses. We intend to finance these expenses with further issuances of securities and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

MATERIAL COMMITMENTS

As of the date of this Annual Report, we do not have any material commitments.

PURCHASE OF SIGNIFICANT EQUIPMENT

As of the date of this Annual Report, we do not anticipate the purchase of any significant equipment.

OFF-BALANCE SHEET ARRANGEMENTS

As of the date of this Annual Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

GOING CONCERN

The independent auditors' report accompanying our March 31, 2017 and March 31, 2016 financial statements contains an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. The financial statements have been prepared "assuming that we will continue as a going concern," which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business.

## Controls and procedures

As filed, 3,037 characters.

### Disclosure Controls and Procedures

Based on an evaluation as of the date of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as required by Exchange Act Rule 13a-15. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2017 to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, to allow timely decisions regarding required disclosure.

### Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate control over financial reporting (as defined in Rule 13a-15(f) promulgated under the Exchange Act. Our management assessed the effectiveness of our internal control over financial reporting as of March 31, 2017. In making this assessment management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the criteria in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013) (COSO). Our management has concluded that, as of March 31, 2017, our internal control over financial reporting is effective based on these criteria.

### Changes in Internal Control and Financial Reporting

There has been no change in our internal control over financial reporting identified in connection with our evaluation we conducted of the effectiveness of our internal control over financial reporting as of March 31, 2017, that occurred during our fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report in this annual report

Filed Aug 17, 2018.
Source: SEC EDGAR, the filing index for accession 0001554795-18-000235. Last ingested by Listed: Oct 24, 2026, 15:13 ET. No prices; not investment advice.
